Subscribe to Newsletter

Contract Manufacturing Services

Manufacture Small Molecules

Are You a Bio-Catalytic Converter?

| Alice Dunbabin

Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.

Manufacture Advanced Medicine

Modular Flexibility in the Manufacturing Multiverse

| Sponsored by CRB

Facilities must be flexible enough to cope with multiple modalities, including cell and gene therapies.

Business & Regulation COVID-19

Facing the COVID-19 Crisis: Leadership and the Future of Pharma

As part of the CPhI Festival of Pharma 2020, we brought together experts from our annual Power List to discuss the impact of COVID-19 on the industry.

Manufacture Contract Manufacturing Services

Precious Metal Catalysts: The Scavengers’ Guide

| Philip Wheeler, Dirk Rickert, Thorsten Rieke

Platinum group (and other precious) metal catalysts are inherently expensive, so why not recover and recycle?

Manufacture Contract Manufacturing Services

Getting the Job (Done)

| Stephanie Vine

Sitting Down With… Will Downie, CEO of Vectura Group, UK, to discuss his career and passion for business.

Business & Regulation Business Practice

The Pandemic Diaries

| Erik Haeffler, Don O’Callaghan, Amélie Boulais

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

Manufacture Bioprocessing - Upstream & Downstream

Fighting Viruses with Enhanced ADCC

| Andrew J Racher

Researchers are always looking for new ways to improve effectiveness of antibody therapy.

Discovery & Development Contract Manufacturing Services

Getting a Handle on High Potency

| Maryam Mahdi

How can companies avoid the risks of HPAPI containment and handling?

Manufacture Advanced Medicine

Serving a Rising Power

| Sponsored by GenScript Probio

The gene and cell therapy market is growing, but does it have the CDMO support needed to maintain its upward trajectory?

Manufacture Vaccines

Success at Speed Part 4: Commercial Manufacturing

| Amélie Boulais, Piergiuseppe Nestola

A typical vaccine takes around 10 to 12 years to reach the market. A key question: “Where should we base production?”

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register